Nucleic acids are chemical substances and carry genetic information of the cell. The three types of nucleic acids are deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and artificial nucleic acid. Watson-Crick base pairing recognizes endogenous nucleic acids in a sequence-specific manner, mediating the shared mode of action of all nucleic acids. The nucleic acid-based therapies are widely used to treat various chronic diseases. Nucleic acid shows the significant therapeutic result in chronic diseases, such as cancer, tumor, diabetes, tuberculosis, and human immunodeficiency virus (HIV). For instance, in recent years, the global nucleic acid therapeutics has gained extensive attention. Moreover, the increasing chronic illnesses and the search for cure of chronic illnesses is an international concern, therefore nucleic acid therapeutics is observing increased attention.
The nucleic acid therapeutics shows long lasting effects through gene editing, gene inhibition, gene addition or gene replacement. Furthermore, the increase in chronic disease prevalence and patients seeking treatment of nucleic acid therapies help in the global nucleic acid therapeutics market growth. Nucleic acid therapeutics shows the long lasting and curative effects. The key drivers for the growth of the global nucleic acid therapeutics market are increasing chronic illness and immensely developing novel treatments of nucleic acids. The high cost of research and development and expensive treatments and technologies are some major elements restraining the market growth. High product demand and growing concentration of pharmaceutical companies on the development of treatment for nucleic acid therapeutics are additional factors that are driving the nucleic acid therapeutics market growth. The lack of treatment alternatives for cancer, muscular dystrophy, and human immunodeficiency virus (HIV) is the important reason for global nucleic acid therapeutics market expansion. The nucleic acid therapeutics market will revamp on approval of the developing therapies for amyloidosis by using antisense oligonucleotide to lower transthyretin (TTR) levels and dose escalation to investigate safety of ISTH0036 in glaucoma undergoing trabeculectomy patients. For instance, there are various therapies under pipeline, which are expected to serve the demand for nucleic acid therapies globally and contribute to the market growth.
The nucleic acid therapeutics is segmented on the basis of products, application, end user, and region. Based on the products, the market is bifurcated into anti-sense oligonucleotides (ASOS) and DNA aptamers, RNA interference [RNAi] and short interfering RNAs [siRNAs], and others. The others segment is further classified into antagomir and RNA sponge and locked nucleic acid. By application, the market is fragmented into monogenetic disorders and multi-genetic disorders. By end user, the market is segmented into hospitals & clinics and academic & research institutes.
Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Major key players that operate in the global nucleic acid therapeutics market are Agilent Technologies Inc., Alnylam Pharmaceuticals, Inc., Arbutus Biopharma Corporation, Arrowhead Pharmaceuticals, Benetic Biopharma, Inc., Caperna Inc. [Moderna], Copernicus Therapeutics, Genzyme (Sanofi), Ionis Pharmaceuticals, MERCK KGAA, Novartis AG, Phylogica, Protagonist Therapeutics, QIAGEN N.V., Sarepta Therapeutics, Silence Therapeutics plc., and Thermo Fisher Scientific Inc.
The nucleic acid therapeutics shows long lasting effects through gene editing, gene inhibition, gene addition or gene replacement. Furthermore, the increase in chronic disease prevalence and patients seeking treatment of nucleic acid therapies help in the global nucleic acid therapeutics market growth. Nucleic acid therapeutics shows the long lasting and curative effects. The key drivers for the growth of the global nucleic acid therapeutics market are increasing chronic illness and immensely developing novel treatments of nucleic acids. The high cost of research and development and expensive treatments and technologies are some major elements restraining the market growth. High product demand and growing concentration of pharmaceutical companies on the development of treatment for nucleic acid therapeutics are additional factors that are driving the nucleic acid therapeutics market growth. The lack of treatment alternatives for cancer, muscular dystrophy, and human immunodeficiency virus (HIV) is the important reason for global nucleic acid therapeutics market expansion. The nucleic acid therapeutics market will revamp on approval of the developing therapies for amyloidosis by using antisense oligonucleotide to lower transthyretin (TTR) levels and dose escalation to investigate safety of ISTH0036 in glaucoma undergoing trabeculectomy patients. For instance, there are various therapies under pipeline, which are expected to serve the demand for nucleic acid therapies globally and contribute to the market growth.
The nucleic acid therapeutics is segmented on the basis of products, application, end user, and region. Based on the products, the market is bifurcated into anti-sense oligonucleotides (ASOS) and DNA aptamers, RNA interference [RNAi] and short interfering RNAs [siRNAs], and others. The others segment is further classified into antagomir and RNA sponge and locked nucleic acid. By application, the market is fragmented into monogenetic disorders and multi-genetic disorders. By end user, the market is segmented into hospitals & clinics and academic & research institutes.
Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Major key players that operate in the global nucleic acid therapeutics market are Agilent Technologies Inc., Alnylam Pharmaceuticals, Inc., Arbutus Biopharma Corporation, Arrowhead Pharmaceuticals, Benetic Biopharma, Inc., Caperna Inc. [Moderna], Copernicus Therapeutics, Genzyme (Sanofi), Ionis Pharmaceuticals, MERCK KGAA, Novartis AG, Phylogica, Protagonist Therapeutics, QIAGEN N.V., Sarepta Therapeutics, Silence Therapeutics plc., and Thermo Fisher Scientific Inc.
KEY BENEFITS FOR STAKEHOLDERS
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the nucleic acid therapeutics market analysis from 2021 to 2031 to identify the prevailing nucleic acid therapeutics market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the nucleic acid therapeutics market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global nucleic acid therapeutics market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Products
- Anti-Sense Oligonucleotides (ASOs) and DNA Aptamers
- RNA interference [RNAi] and short interfering RNAs [siRNAs]
- Others
By Application
- Monogenetic disorders
- Multi-genetic disorders
By End User
- Hospitals and Clinics
- Academic and Research Institutes
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Agilent Technologies
- Alnylam Pharmaceuticals
- Arbutus Biopharma
- Arrrowhead
- Benitec Biopharma
- Caperna
- Copernicus
- Genzyme Sanofi
- Ionis Pharmaceuticals
- Merck
- Novartis A.G
- PYC Therapeutics Limited
- Protagonist Therapeutics
- Qaigen NV
- Sarpeta Therapeutics
- Silence Therapeutics
- Thermo Fisher Scientific
- Wavelifesciences
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: NUCLEIC ACID THERAPEUTICS MARKET, BY PRODUCTS
CHAPTER 5: NUCLEIC ACID THERAPEUTICS MARKET, BY APPLICATION
CHAPTER 6: NUCLEIC ACID THERAPEUTICS MARKET, BY END USER
CHAPTER 7: NUCLEIC ACID THERAPEUTICS MARKET, BY REGION
CHAPTER 8: COMPANY LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
According to the report, titled, “Nucleic Acid Therapeutics Market," the nucleic acid therapeutics market was valued at $4.1 billion in 2021, and is estimated to reach $12.2 billion by 2031, growing at a CAGR of 11.6% from 2022 to 2031.The basic polymers deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) have been extensively studied over the past two decades and are now being considered as stand-alone medicinal agents. Much of the development has resulted from the realization that they perform a wide range of tasks that go beyond simple protein production and genetic information storage. Many of nucleic acid substances have regulatory authorization for usage in humans, and many are currently undergoing clinical trials. Fomivirsen, developed by Ionis Pharmaceuticals in 1998 for the treatment of cytomegalovirus (CMV) retinitis, is the first ASO to be approved for use in humans. The siRNAs are double-stranded molecules with a short length of 21-23 nucleotides, synthesized chemically and are most stable. The global nucleic acid therapeutics market size is to expand as more R&D activities are conducted in an effort to create an effective treatment. the driving factors which are boosting the market during nucleic acid therapeutics market forecast are expanding government programs and investments for the development of innovative gene therapies. Spreading more consciousness about various chronic illnesses will also contribute to global nucleic acid therapeutics market growth. The nucleic acid therapeutics market analysis from 2021 to 2031 to identify the prevailing nucleic acid therapeutics market opportunity.
The nucleic acid therapeutics industry is expected to grow rapidly due to various new therapies in the approval and developmental stages. Furthermore, nucleic acid therapeutics market trends is also to advance due to the expansion of the pharmaceutical, healthcare industries, biological products developments, and DNA-based therapies. On the other hand, lack of expertise, minimum availability of technologies, and high cost of treatment may restrain the expansion of the global nucleic acid therapeutics market size. Furthermore, the need for nucleic acid therapeutics significantly decreased after the COVID-19 pandemic. The focus of medical professionals, governments, and the general public has moved to containing the virus's spread as a result of the fatal virus's quick expansion. It consequently decreased the need for nucleic acid therapies. People visited clinics and hospitals only if they had an emergency, due to which, various other diseases were ignored by the healthcare professionals. As a result, the COVID-19 pandemic caused severe disruptions in the market for diagnosis and treatment of the nucleic acid therapeutics.
Coronavirus Severe acute respiration syndrome (SARS-CoV-2) is an infectious disease caused by the novel coronavirus (COVID-19), which originated in the Wuhan district in China in the late 2019, and since has spread to 212 countries. The virus was initially referred to as “novel coronavirus 2019” (2019-nCoV) by the WHO, However, on February 11, 2020, it was given the official name of SARS-CoV-2 by the International Committee on Taxonomy of Viruses. WHO declared COVID-19 as pandemic on March 11, 2020, and by September 1, 2020, over 28.1 million people have been infected globally with over 909,000 deaths. COVID-19 symptoms include fever, cough, and shortness of breath.
Nearly all industries have been impacted by the global public health pandemic, COVID-19. As coronavirus crises sweep the globe and force healthcare organizations to devote the majority of their funds to fight COVID-19, it has also resulted in a significant decline in demand for the nucleic acid therapeutics market share across several sectors, particularly the health and pharmaceutical sectors. The main cause of the interruptions experienced by patients getting treatment for nucleic acid therapeutics in hospitals was the risk of infection. The treatments based on nucleic acid require hospitalization, hence the market growth declined during this period. As a result, the COVID-19 outbreak slowed down the global market growth for treatments of nucleic acid therapeutics, which was expected to have a negative effect on the market's value in 2020 and beyond.
By products, the anti-sense oligonucleotides (ASOS) and DNA aptamers segment dominated the market in 2021. The factors responsible for the product segment growth are increased in anti-sense oligonucleotides (ASOS) and DNA aptamers product offering and increase in approval of the novel treatments. For instance, Nusinersen was approved by the FDA in 2016 for the treatment of neurological disorders by administration of ASOS intrathecally and Viltepso (Viltolarsen) was approved by FDA and marketed in 2020 for the treatment of muscular dystrophy. Furthermore, increased demand and approval for novel therapies supported the segment growth during forecast period.
Depending on application, monogenetic disorders segment dominated the market in 2021 and is expected to remain dominant during the forecast period. The variation or mutation in the single gene leads to monogenetic disorders. The prevalence of monogenetic disorders is high as it is inherited from parents to newborns. Monogenetic disorders include, cystic fibrosis, muscular dystrophy, sickle cell anemia, marfan syndrome, and others. According to World Health Organization, there are about 5,000 types of monogenetic disorders known till today. Moreover, new therapies are being developed for the treatment of monogenetic disorders.
On the basis of end user, the hospital and clinics segment dominated the market in 2021 and is expected to remain dominant during the forecast period. The market growth of this segment is driven by the increased patient treatments. The nucleic acid therapies are given to the patient in hospitals as these treatments are done by the expert doctors and professional physicians hence the segment generate higher revenue.
Region-wise, in nucleic acid therapeutics industry, North America has the highest market share. North America advances due to availability of treatments, new developing therapies of nucleic acids, and increased monogenetic disease count in the U.S. and Mexico.
Key Findings of the Study
- Based on products, the RNA interference [RNAi] and short interfering RNAs [siRNAs] segment dominated the market in 2021.
- Based on application, the monogenetic disorders segment dominated the market in 2021.
- On the basis of end user, the hospitals & clinics segment dominated the market in 2021.
- On the basis of region, North America dominated the market in 2021 and is expected to dominate during the forecast period
Companies Mentioned
- Agilent Technologies
- Alnylam Pharmaceuticals
- Arbutus Biopharma
- Arrrowhead
- Benitec Biopharma
- Caperna
- Copernicus
- Genzyme Sanofi
- Ionis Pharmaceuticals
- Merck
- Novartis A.G
- Pyc Therapeutics Limited
- Protagonist Therapeutics
- Qaigen Nv
- Sarpeta Therapeutics
- Silence Therapeutics
- Thermo Fisher Scientific
- Wavelifesciences
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
